Financial News

Nektar Therapeutics reports upbeat study results

Nektar Therapeutics (Nasdaq: NKTR) reported positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181 sending the stock price soaring $6.61 to close at $22.11.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback